Structure Therapeutics (NASDAQ:GPCR) Earns "Overweight" Rating from Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Structure Therapeutics (NASDAQ:GPCR - Free Report) in a research report released on Thursday, Benzinga reports. The brokerage currently has a $65.00 price objective on the stock.

Separately, Lifesci Capital reaffirmed an outperform rating on shares of Structure Therapeutics in a research note on Tuesday, February 27th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Structure Therapeutics presently has an average rating of Buy and an average target price of $85.71.

Structure Therapeutics Trading Down 2.4 %

NASDAQ:GPCR traded down $0.89 on Thursday, hitting $36.18. The company had a trading volume of 379,626 shares, compared to its average volume of 579,398. The stock has a market capitalization of $1.69 billion and a price-to-earnings ratio of -44.02. The firm has a 50 day moving average of $41.02 and a two-hundred day moving average of $48.70. Structure Therapeutics has a 52 week low of $21.79 and a 52 week high of $75.02.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its quarterly earnings results on Friday, March 8th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.04. As a group, equities analysts forecast that Structure Therapeutics will post -0.98 EPS for the current year.

Hedge Funds Weigh In On Structure Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP raised its stake in Structure Therapeutics by 404.0% during the fourth quarter. Wellington Management Group LLP now owns 4,372,326 shares of the company's stock worth $178,216,000 after buying an additional 3,504,747 shares during the last quarter. Avoro Capital Advisors LLC raised its stake in Structure Therapeutics by 133.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,333,333 shares of the company's stock worth $95,107,000 after buying an additional 1,333,333 shares during the last quarter. Federated Hermes Inc. grew its holdings in Structure Therapeutics by 104.2% in the fourth quarter. Federated Hermes Inc. now owns 2,267,206 shares of the company's stock worth $92,411,000 after purchasing an additional 1,157,006 shares during the period. Adage Capital Partners GP L.L.C. grew its holdings in Structure Therapeutics by 835.5% in the third quarter. Adage Capital Partners GP L.L.C. now owns 1,799,923 shares of the company's stock worth $90,752,000 after purchasing an additional 1,607,525 shares during the period. Finally, FMR LLC grew its holdings in Structure Therapeutics by 28.5% in the third quarter. FMR LLC now owns 1,590,335 shares of the company's stock worth $80,185,000 after purchasing an additional 352,600 shares during the period. Institutional investors own 91.78% of the company's stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.